Which FIH Decisions Are Hardest To Reverse Later?

First-in-human oncology trials are often described as flexible, yet many of the most consequential choices made early on quietly narrow future options. Initial dose selection and escalation strategies shape how safety signals are interpreted, how regulators view risk, and how confidently a therapeutic window can be defended. Once these assumptions are set, later adjustments rarely feel neutral.

Equally enduring are decisions around safety governance. Monitoring models, review committee structures, and escalation authority tend to be locked in early, making mid-trial changes disruptive and credibility‑eroding. Translational and biomarker strategies carry similar weight. Early missteps can limit mechanistic insight, dose justification, or patient selection in ways that cannot be fully corrected later, particularly when sample availability is constrained.

Regulatory positioning, site strategy, investigator engagement, and internal decision cadence round out a set of choices that often persist well beyond the FIH phase. Together, they influence speed, consistency, and strategic momentum across the program. Recognizing which decisions are hardest to reverse allows teams to invest rigor where it matters most — before flexibility disappears. Explore the full guide for a practical framework to protect optionality and long‑term credibility.